01541 IMMUNEONCO-B
- 14.580
- -0.120-0.82%
IMMUNEONCO-B News
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) Institutional Investors Have Had a Good Week as Stock Gains 8.6%
Key Insights Given the large stake in the stock by institutions, ImmuneOnco Biopharmaceuticals (Shanghai)'s stock price might be vulnerable to their trading decisions A total of 5 investors have a m
HK stocks volatile | In the afternoon, Yiming Angke-B (01541) soared over 17% and was granted approval for phase III clinical trials of Tislelizumab for the treatment of leukemia.
At the end of the trading day, E-mart (01541) soared more than 17% and as of press time, rose by 11.5%, to HKD 16.1, with a turnover of HKD 4.9677 million.
Yimingangkang-B (01541): CD47 targeted drug two verbal reports appeared in ASCO, IMM01 overall response rate outstanding.
Yimingangco-B (01541) recently presented two Phase II clinical trial data of its core product Timdarpacept (project number: IMM01) in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug
China's medical products administrator approved ImmuneOnco Biopharmaceuticals' (HKG:1541) phase 3 clinical trial for its IMM01 treatment for chronic myelomonocytic leukemia, according to a Monday fili
Yiming Angko-B (01541.HK): IMM01 (tidapecip) combined with azacitidine was approved by the State Drug Administration for phase III clinical trial of CMML first-line treatment
On June 3, Ge Longhui | Yiming Angko-B (01541.HK) announced that the Group was approved by the China National Drug Administration (“State Drug Administration”) Drug Evaluation Center (“Drug Evaluation Center”) to conduct IMM01 (tidapecip) combined with azacitidine phase III clinical trial plan for first-line treatment of chronic granulocytic monocytic leukemia (CMML).
Express News | ImmuneOnco Biopharmaceuticals Shanghai - Approval by Nmpa for First-Line Treatment of Cmml
Express News | ImmuneOnco Biopharmaceuticals Shanghai - Approval by Nmpa for Phase III Clinical Trial of Imm01 (Timdarpacept) in Combination With Azacitidine
Yiming Angko-B (01541): The China Securities Regulatory Commission issued a notice of record regarding the full circulation of certain H shares of the company's unlisted shares
According to the Zhitong Finance App, Yiming Angko-B (01541) issued an announcement. The company has recently received a filing notice from the China Securities Regulatory Commission to implement the full circulation of the company's H shares. According to the filing notice, the company has completed the implementation filing with the China Securities Regulatory Commission on the conversion of up to 120 million unlisted shares of the company to H shares of the company. The filing notice is valid for 12 months from May 14, 2024. The company will apply to the Stock Exchange for approval to list and trade the relevant H shares on the main board of the Stock Exchange. As of the date of this announcement, the details of the implementation plan for conversion and listing have not been finalized.
Yiming Angko-B (01541.HK) appoints Guan Mei as Executive Director
Gelonghui, May 28 | Yiming Angko-B (01541.HK) announced that after shareholders' approval at the annual shareholders' meeting, Ms. Guan Mei was appointed as the executive director of the first board of directors. Ms. Kwan's term of office will begin on May 28, 2024 and end when the first term of the board expires.
Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China
Immuneonco Biopharmaceuticals (HKG:1541) has obtained approval from the National Medical Products Administration of China to conduct a phase III clinical trial of IMM01 (Timdarpacept) in combination w
Yiming Angko-B (01541.HK): IMM01 (tidapecip) combined with azacitidine was approved by the State Drug Administration to conduct a randomized, double-blind, controlled phase III clinical trial plan
Gelonghui, May 17 | Yiming Angko-B (01541.HK) issued an announcement. The Group was approved by the Drug Evaluation Center of the State Drug Administration (“Drug Evaluation Center”) to conduct a randomized, double-blind, controlled IMM01 (tidapecip) combined with azacitidine phase III clinical trial plan for first-line treatment of high-risk myelodysplastic syndrome (HRMDS). Furthermore, the latest results of the IMM01 (tidapecip) combined with azacitidine phase II clinical trial program have been accepted by the 2024 American Society of Clinical Oncology (“ASC”) to be held in Chicago on June 1, 2024
宜明昂科-B：2023年報
Gelonghui Announcements Selected (Hong Kong Stock) | Xiaopeng Automobile-W (09868.HK) signs strategic cooperation framework agreement with Volkswagen Group on electronic and electrical architecture technology
[Today's Focus] Xiaopeng Motor-W (09868.HK) and Volkswagen Group sign a strategic cooperation framework agreement on electronic and electrical architecture technology Xiaopeng Motor-W (09868.HK) and Volkswagen Group jointly announced that Xiaopeng Motor and Volkswagen Group have signed a strategic cooperation framework agreement on electronic and electrical architecture (“electronic and electrical architecture”) technology. The industry-leading electronic and electrical architecture independently developed by Xiaopeng Motor is the core technology of its vertically integrated software and hardware technology. Thanks to this advanced electronic and electrical architecture, software such as intelligent driving assistance software and connected vehicle operating systems can be decoupled from the underlying hardware and vehicle platform,
Yiming Angko-B (01541.HK): IMM01 (tidapecip) was approved by the State Drug Administration for phase III clinical trial program
Gelonghui, April 17 | Yiming Angko-B (01541.HK) announced that in April 2024, the Group has obtained approval from the China National Drug Administration for recurrent or refractory (R/R) classic Hodgkin lymphoma (cL) that recurs or progresses after treatment with IMM01 (tidapacept) and tirelizumab in combination therapy with procedural cellular death protein 1 (PD-1) inhibitors. The Group's core product IMM01 (tidapecip) is an innovative targeting differentiation cluster 47 (CD47) molecule. This product is the first to enter China
Cansino Biotech (06185), the leading healthcare market, surged 15.12%, and Beijing, Guangzhou, and Zhuhai issued pharmaceutical innovation support policies
Jinwu Financial News | The healthcare sector led the market. Hang Seng Healthcare Index rose 1.93%. Among the constituent stocks, Cansino Biotech (06185) rose 15.12%, Junshi Biotech (01877) rose 11.9%, Genting Xinyao (01952) rose 7.8%, Yiming Angke (01541) rose 7.79%, Pharmaceuticals (02268) rose 5.98%, and Tiger Pharmaceuticals (03347) rose 5.8%. According to the news, the Beijing Municipal Medical Security Administration issued “On “Certain Measures to Support the High-Quality Development of Innovative Pharmaceuticals by 9 Departments Including the Beijing Municipal Medical Security Administration” (202
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases
Immuneonco Biopharmaceuticals' (HKG:1541) loss narrowed to 379.5 million yuan or 1.05 yuan per share, in 2023, from 402.9 million yuan, or 1.21 yuan per share, in 2022, according to a Tuesday filing w
Yiming Enko-B (01541.HK) reduced its annual net loss to 380 million yuan, continuing to rapidly advance the development of drug pipelines
On March 25, GLONGHUI | Yiming Angko-B (01541.HK) announced its annual results. The Group's loss during the year was reduced from RMB 402.9 million for the year ended December 31, 2022 to RMB 379.5 million for the year ended December 31, 2023. R&D expenditure increased 5.3% from RMB 277.3 million for the year ended 31 December 2022 to RMB 291.9 million for the year ended 31 December 2023, mainly due to (i) an increase of RMB 24 in clinical trial expenses due to the progress of clinical drug candidates
Yiming Onko-B (01541) will continue to support R&D in 2023
Yiming Angko-B (01541) announced its 2023 results, with revenue of about 386,000 yuan and an increase in R&D expenses by 5...
IMMUNEONCO-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Changes in Hong Kong stocks | Yiming Enko-B (01541) quickly rose by more than 20%. The company will hold a board meeting next Monday to consider and approve annual results
Yiming Enko-B (01541) quickly rose by more than 20%. As of press release, it rose 20.27% to HK$17.8, with a turnover of HK$3.31 million.
Analysis
Price Target
No Data
